Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Oct 24, 2014
Last Price Change Open Day High 52-Week High
0.92  up   (3.872%) 23.60 25.25 30.38
Volume Previous Close Day Low 52-Week Low
417,000 23.76 23.47 10.90

View all »   RSSRecent Releases

Oct 21, 2014
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

Oct 15, 2014
Esperion Therapeutics Prices Public Offering of Common Stock